Monoclonal Antibodies Protect Against Respiratory Syncytial Virus

Detection of bovine respiratory syncytial virus in experimentally infected balb/c mice

“…Collins et al [10] have pointed out that a wide range of animals, including marmosets, nonhuman primates, ferrets, mink, chinchillas, guinea pigs, cotton rats and mice, could be experimentally infected when RSV is inoculated directly into the respiratory tract. Small experimental animals have been used as models of lower respiratory tract infection with RSV [5,8,9,15,17,19,24,25]. The present study detected BRSV in experimentally infected balb/c mice by RT-nested-PCR and immunohistochemistry.…”

“…In this study, balb/c mice were elected to be infected with the BRSV-25-BR strain due to the impossibility of maintaining large experimental animals -such as calves -in our institution. Several authors have used this lineage mice during experiments carried out with HRSV [4,11,17,24,25] and BRSV [4]. According to Kumar et al [17], balb/c mice provide a good model for the study of infection by HRSV, in which the infection duration and the pulmonary pathology resembles those in human beings.…”

The good and evil of complement activation in HIV-1 infection

“…85 Taylor reported on mice inoculated with 25 monoclonal Abs (mAbs) intravenously to test Ab-mediated anti-respiratory syncytial virus (RSV) activity against intranasal challenge with RSV. 86 Two mAbs (R13-1 and R281-1, both to RSV F protein) gave similar levels of protection against infection, although the neutralization titer of R281-1 was 50 times greater than that of R13-1. In addition, two other mAbs (R18-3 and R402-5, both to RSV GP84) reduced viral titer 10-to 100-fold compared with control mice, yet neither had detectable neutralizing activity.…”

“…[84][85][86][87] An in vivo study in TgH (KL25) mice showed that non-nAbs binding to the neutralizing antigenic sites on the lymphocytic choriomeningitis virus surface glycoprotein exerted an important biological effect by limiting early virus replication and spread. 84 In studies of mechanisms of protection against rotavirus infection and disease, nAbs have been found to be protective, but non-nAbs demonstrated important effector properties as well.…”

“…In addition, two other mAbs (R18-3 and R402-5, both to RSV GP84) reduced viral titer 10-to 100-fold compared with control mice, yet neither had detectable neutralizing activity. 86 Similarly, Walsh et al passively immunized cotton rats with nine mAbs with cross-reactive antigenic sites, thus reducing pulmonary virus titers of both A and B RSV subtypes. 87 The protection, however, did not correlate with in vitro neutralizing capacity.…”